

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-213940P	20000626 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Hopgood, Calimafde, Kalil & Judlowe, LLP, Suite 4000, 60 East 42nd St., New York, NY, 10165	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	630	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Photoaging of human skin, such as evidenced by the increased presence of matrix metalloproteinases after exposure to **UV** radiation, is prevented by pretreating the skin with an inhibitor of epidermal growth factor receptor (EGF-R) prior to exposure. Such inhibitor are preferably natural, an example of which is **genistein**. Compositions used for such purposes preferably include an EGF-R as well as another MMP inhibitor, such as a retinoid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 1 OF 2 USPATFULL

ACCESSION NUMBER: 2002:251740 USPATFULL
TITLE: Use of natural EGFR inhibitors to prevent side effects
due to retinoid therapy, soaps, and other stimuli that
activate the epidermal growth factor receptor
INVENTOR(S): Kang, Sewon, Ann Arbor, MI, UNITED STATES
Fisher, Gray J., Ypsilanti, MI, UNITED STATES
Voorhees, John J., Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137693	A1	20020926
APPLICATION INFO.:	US 2002-85978	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271894P	20010227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Bradley N. Ruben, Suite 5A, 463 First Street, Hoboken, NJ, 07030	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	714	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Many human conditions, often skin conditions, are treated topically or orally with a retinoid such as **retinoic acid** or acetretin, which treatment often has the side effect of dry, irritated, and/or peeling skin. The use of soaps, detergents, chemical irritants, and such can also cause these same side effects. These side effects can be reduced or eliminated by the topical administration of an inhibitor, especially a natural inhibitor, of the epidermal growth factor receptor (EGFR), administered concomitantly with the retinoid, separately from the retinoid (such as on an as needed basis), or both. Administration of the two together is facilitated by a composition suitable for topical application and comprising both the retinoid and a natural EGFR inhibitor. Preferred natural inhibitors are **genistein** and other isoflavones extracted from natural occurring substances, or simple derivatives of such substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 2 USPATFULL

ACCESSION NUMBER: 2002:21806 USPATFULL
TITLE: Use of **EGF-R protein**
tyrosine **kinase inhibitors** for
preventing photoaging in human skin
INVENTOR(S): Voorhees, John J., Ann Arbor, MI, UNITED STATES
Fisher, Gary J., Ypsilanti, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012641	A1	20020131